NCT03842085: Phase I Clinical Study of MBS301 in Treatment of HER2 Positive Recurrent or Metastatic Malignant Solid Tumor |
|
|
| Recruiting | 1 | 34 | RoW | Recombinant Humanized Bispecific Monoclonal Antibody MBS301, MBS301 | Beijing Mabworks Biotech Co., Ltd. | HER2-positive Recurrent or Metastatic Malignant Solid Tumor | 12/24 | 12/25 | | |
